Our data demonstrated that IL-2 therapy suppressed GVHD and improved the overall survival without the evidence of cancer growth until week 6 (Figures 6E, F), suggesting that IL-2-expanded Treg under mild inflammatory conditions did not interfere with the GVL activity. This evidence concerns the gene IL2 and graft versus host disease.